INSMED Inc
INSM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001104506
In the last 90 days, INSMED Inc insiders filed 0 open-market purchases and 7 sales; 667 institutions reported holding it in 13F filings for Q2 2026, worth $23.8B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $42.9M in total
- 7
- 13F holdersQ2 2026, −3 vs. previous quarter
- 667
- 13F valueReported value at the end of Q2 2026
- $23.8B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding INSM, Q2 2026
2 superinvestors report holding INSMED Inc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
3.5%
INSMED Inc's share of the portfolio
- Shares
- 1,424,690
- Value
- $151.9M
Latest insider trades
Open-market purchases and sales by INSMED Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 (view filing)4:04 PM ET | Sep 9 | 2 days | Brennan David RDirector | SSale | −25.0K | $124.00 | −$3.10M | −38.9%39.2K after | |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17 | 2 days | Sharoky Melvin MDDirector | SSale | −5.00K | $127.53 | −$637.6K | −100.0%0 after | |
| Aug 12, 2026 (view filing)5:04 PM ET | Aug 10 | 2 days | Adsett RogerChief Operating Officer | SSale | −239.8K | $133.27 | −$32.0M | −70.8%98.7K after | |
| Aug 7, 2026 (view filing)4:39 PM ET | Aug 6 | 1 day | Flammer Martina M.D.Chief Medical Officer | SSale | −27.2K | $128.61 | −$3.49M | −31.0%60.5K after | 2 lots10b5-1 |
| Jul 24, 2026 (view filing)5:02 PM ET | Jul 23 | 1 day | Lewis WilliamChair and CEO | SSale | −10.7K | $106.06 | −$1.13M | −4.0%259.1K after | 2 lots10b5-1 |
| Jul 10, 2026 (view filing)4:02 PM ET | Jul 9 | 1 day | Lewis WilliamChair and CEO | SSale | −10.7K | $117.40 | −$1.26M | −4.0%259.1K after | 3 lots10b5-1 |
| Jul 8, 2026 (view filing)4:03 PM ET | Jul 6 | 2 days | Flammer Martina M.D.Chief Medical Officer | SSale | −12.3K | $109.98 | −$1.35M | −16.9%60.5K after | 2 lots10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Lewis WilliamChair and CEO | SSale | −21.4K | $103.32 | −$2.21M | −7.6%258.9K after | 5 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Smith Michael AlexanderChief Legal Officer | SSale | −1.81K | $95.82 | −$173.1K | −4.6%37.6K after | 10b5-1 |
| Jun 10, 2026 (view filing) | Jun 8 | 2 days | Lewis WilliamChair and CEO | SSale | −6.51K | $94.03 | −$612.6K | −2.5%258.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in INSMED Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 16,143,583 | $1.72B | 0.07% | +2,983,416+22.7% | Added |
| BlackRock, Inc. | 15,807,984 | $1.69B | 0.03% | −870,162−5.2% | Reduced |
| Vanguard Portfolio Management LLC | 10,407,962 | $1.11B | 0.05% | +36,160+0.3% | Added |
| JPMorgan Chase & Co | 10,428,170 | $1.09B | 0.06% | −13,722,329−56.8% | Reduced |
| Vanguard Capital Management LLC | 9,790,865 | $1.04B | 0.02% | +148,734+1.5% | Added |
| Baker Bros. Advisors LP | 8,796,111 | $937.8M | 4.70% | +1,375,000+18.5% | Added |
| Capital International Investors | 8,238,124 | $878.3M | 0.18% | +2,642,930+47.2% | Added |
| Darwin Global Management, Ltd. | 6,431,163 | $673.6M | 17.91% | −10,374,021−61.7% | Reduced |
| Ameriprise Financial Inc | 6,179,571 | $658.9M | 0.13% | +3,121,853+102.1% | Added |
| Orbis Allan Gray Ltd | 6,076,487 | $647.9M | 2.23% | +4,203,663+224.5% | Added |